The bioavailability and pharmacodynamics of different concentrations of omega-3 acid ethyl esters
- PMID: 16806871
- DOI: 10.1016/j.plefa.2006.04.003
The bioavailability and pharmacodynamics of different concentrations of omega-3 acid ethyl esters
Abstract
Omega-3 fatty acids have a long history of use as dietary supplements and more recently for therapeutic applications as prescription pharmaceuticals. Achieving a high concentration is critical for developing convenient, practical therapeutic formulations. The objective of the study was to explore the uptake and effects of different concentrations of omega-3 acid ethyl esters. Three different omega-3 concentrations were investigated in a clinical study with 101 subjects. All participants were dosed for 14 days with 5.1g per day of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) ethyl esters provided in three concentrations: 62.5%, 80% and 85% of total fatty acids. Key endpoints of the study were serum phospholipids and standard fasting lipid panels at day 14. Although administered the same quantity of omega-3 fatty acids, the patients taking the more concentrated formulations had higher levels of EPA/DHA in serum phospholipids and greater reductions in serum triglyceride and VLDL cholesterol levels. Total and non-HDL cholesterol were significantly reduced from baseline with all three formulations. In conclusion the concentration of omega-3 fatty acids of the formulations studied had independent effects on the uptake and effect outcomes during short-term administration. Very high concentrations of omega-3 acid ethyl esters (80%) appear to have higher uptake and are more potent for reducing triglycerides (TGs) and VLDL-cholesterol than formulations with lower concentrations.
Similar articles
-
Bioavailability of marine n-3 fatty acid formulations.Prostaglandins Leukot Essent Fatty Acids. 2010 Sep;83(3):137-41. doi: 10.1016/j.plefa.2010.06.007. Prostaglandins Leukot Essent Fatty Acids. 2010. PMID: 20638827 Clinical Trial.
-
Risk stratification by the "EPA+DHA level" and the "EPA/AA ratio" focus on anti-inflammatory and antiarrhythmogenic effects of long-chain omega-3 fatty acids.Herz. 2004 Nov;29(7):673-85. doi: 10.1007/s00059-004-2602-4. Herz. 2004. PMID: 15580322 Review.
-
Enhanced increase of omega-3 index in response to long-term n-3 fatty acid supplementation from triacylglycerides versus ethyl esters.Eur J Clin Nutr. 2011 Feb;65(2):247-54. doi: 10.1038/ejcn.2010.239. Epub 2010 Nov 10. Eur J Clin Nutr. 2011. PMID: 21063431 Clinical Trial.
-
A novel omega-3 free fatty acid formulation has dramatically improved bioavailability during a low-fat diet compared with omega-3-acid ethyl esters: the ECLIPSE (Epanova(®) compared to Lovaza(®) in a pharmacokinetic single-dose evaluation) study.J Clin Lipidol. 2012 Nov-Dec;6(6):573-84. doi: 10.1016/j.jacl.2012.01.002. Epub 2012 Jan 24. J Clin Lipidol. 2012. PMID: 23312053 Clinical Trial.
-
Role of prescription omega-3 fatty acids in the treatment of hypertriglyceridemia.Pharmacotherapy. 2007 May;27(5):715-28. doi: 10.1592/phco.27.5.715. Pharmacotherapy. 2007. PMID: 17461707 Review.
Cited by
-
Pharmacokinetics of omega-3 fatty acids in patients with severe sepsis compared with healthy volunteers: A prospective cohort study.Clin Nutr. 2020 Mar;39(3):958-965. doi: 10.1016/j.clnu.2019.03.040. Epub 2019 Apr 9. Clin Nutr. 2020. PMID: 31005335 Free PMC article.
-
Uses and benefits of omega-3 ethyl esters in patients with cardiovascular disease.J Multidiscip Healthc. 2010 Jul 7;3:79-96. doi: 10.2147/jmdh.s4743. J Multidiscip Healthc. 2010. PMID: 21197357 Free PMC article.
-
Omega-3 ethylester concentrate: a review of its use in secondary prevention post-myocardial infarction and the treatment of hypertriglyceridaemia.Drugs. 2009 May 29;69(8):1077-105. doi: 10.2165/00003495-200969080-00008. Drugs. 2009. PMID: 19496632 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials